Buchumschlag

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Sudipto Mukherjee, Cherrishe Brown‐Bickerstaff, Angelica Falkenstein, Adeola Y. Makinde, Emily Bland, JaLyna Laney, Marné Garretson, David Huggar, Ali McBride
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	HemaSphere
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Efficacy of erythroid‐stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group
von: Maël Heiblig, et al.
Veröffentlicht: (2025)

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes
von: David Rombaut, et al.
Veröffentlicht: (2025)

How I manage luspatercept in transfusion‐dependent beta‐thalassemia
von: Daniele Lello Panzieri, et al.
Veröffentlicht: (2026)

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
von: Baptiste Le Calvez, et al.
Veröffentlicht: (2024)

Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
von: Angela Consagra, et al.
Veröffentlicht: (2025)

Prospective genetic germline evaluation in a consecutive group of adult patients aged <60 years with myelodysplastic syndromes
von: Enrico Attardi, et al.
Veröffentlicht: (2024)

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
von: Francesca Vinchi, et al.
Veröffentlicht: (2024)

“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
von: Shoshana Burke, et al.
Veröffentlicht: (2025)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
von: Cristina A. Tentori, et al.
Veröffentlicht: (2024)

Preclinical efficacy of tasquinimod in myelodysplastic neoplasms: Restoring erythropoiesis and mitigating bone loss
von: Manja Wobus, et al.
Veröffentlicht: (2026)

Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
von: Fabio Efficace, et al.
Veröffentlicht: (2024)

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
von: Aida Santaolalla, et al.
Veröffentlicht: (2026)

Sharper definitions, blurred lines: The clinical aftermath of the revised antiphospholipid syndrome criteria
von: Lauren E. Merz, et al.
Veröffentlicht: (2026)

Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting
von: Katherine Antel, et al.
Veröffentlicht: (2026)

Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)
von: Luca De Carolis, et al.
Veröffentlicht: (2025)

IDALLO study: A retrospective multicenter study of the SFGM‐TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1‐mutated AML after allogeneic hematopoietic cell transplantation
von: Adrien Caillet, et al.
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2025)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
von: Raúl Córdoba, et al.
Veröffentlicht: (2026)

Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition
von: Anna Ossami Saidy, et al.
Veröffentlicht: (2025)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
von: Henri C. Hupe, et al.
Veröffentlicht: (2025)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
von: Jan‐Niklas Eckardt, et al.
Veröffentlicht: (2025)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
von: Konstanze Döhner, et al.
Veröffentlicht: (2025)

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML
von: David A. Sallman, et al.
Veröffentlicht: (2025)

TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis
von: Harmony C. Ketchum, et al.
Veröffentlicht: (2025)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
von: Stephanie Sembill, et al.
Veröffentlicht: (2026)

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
von: Uwe Platzbecker, et al.
Veröffentlicht: (2025)

HELIOS Action: Advancing research, education, and equity in hemoglobinopathies across Europe and beyond
von: Sotiroula Chatzimatthaiou, et al.
Veröffentlicht: (2025)

MMS22L is a novel key actor of normal and pathological erythropoiesis
von: Elia Colin, et al.
Veröffentlicht: (2025)

Correction to “Quality of vitamin K antagonist treatment during the last year of life”
Veröffentlicht: (2025)

Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
von: Daniel Mazza Matos
Veröffentlicht: (2026)

Publication Only
Veröffentlicht: (2025)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
von: Rebeqa Gunnarsson, et al.
Veröffentlicht: (2025)

Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
von: Mwanasha H. Merrill, et al.
Veröffentlicht: (2025)

Patterns of immune recovery after axicabtagene ciloleucel for aggressive B‐cell lymphoma
von: André Airosa Pardal, et al.
Veröffentlicht: (2025)

Minimal residual disease assessment following CD19‐targeted therapy in B‐cell precursor acute lymphoblastic leukemia using standardized 12‐color flow cytometry: A EuroFlow study
von: Martijn W. C. Verbeek, et al.
Veröffentlicht: (2025)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
von: Suzana da Silva‐Benedito, et al.
Veröffentlicht: (2026)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
von: Thomas C. Wiemers, et al.
Veröffentlicht: (2026)

Dynamic evolution of TCF3‐PBX1 leukemias at the single‐cell level under chemotherapy pressure
von: Mira Kusterer, et al.
Veröffentlicht: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Veröffentlicht: (2025)

Issue Information
Veröffentlicht: (2024)